160 related articles for article (PubMed ID: 10761749)
1. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Levy-Piedbois C; Durand-Zaleski I; Juhel H; Schmitt C; Bellanger A; Piedbois P
Ann Oncol; 2000 Feb; 11(2):157-61. PubMed ID: 10761749
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Iveson TJ; Hickish T; Schmitt C; Van Cutsem E
Eur J Cancer; 1999 Dec; 35(13):1796-804. PubMed ID: 10673994
[TBL] [Abstract][Full Text] [Related]
3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
4. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
[TBL] [Abstract][Full Text] [Related]
5. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Hartmann JT; Oechsle K; Jäger E; Reis HE; Haag C; Niederle N; Wilke HJ; Pflüger KH; Batran SA; Büchele T; Hofheinz RD; Kanz L; Bokemeyer C
Anticancer Drugs; 2004 Jun; 15(5):473-7. PubMed ID: 15166621
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
7. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
10. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Comella P; Crucitta E; De Vita F; De Lucia L; Farris A; Del Gaizo F; Palmeri S; Lannelli A; Mancarella S; Tafuto S; Maiorino L; Buzzi F; De Cataldis G;
Ann Oncol; 2002 Jun; 13(6):866-73. PubMed ID: 12123331
[TBL] [Abstract][Full Text] [Related]
11. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
13. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
14. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
15. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
16. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Köhne CH; van Cutsem E; Wils J; Bokemeyer C; El-Serafi M; Lutz MP; Lorenz M; Reichardt P; Rückle-Lanz H; Frickhofen N; Fuchs R; Mergenthaler HG; Langenbuch T; Vanhoefer U; Rougier P; Voigtmann R; Müller L; Genicot B; Anak O; Nordlinger B;
J Clin Oncol; 2005 Aug; 23(22):4856-65. PubMed ID: 15939923
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
19. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T
Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224
[TBL] [Abstract][Full Text] [Related]
20. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
